Imprimis Pharmaceuticals Finds $15M In Debt

San Diego-based Imprimis Pharmaceuticals, a company developing compounded drugs, said thiss morning that it has scored $15M in a term loan. The debt funding came rom Life Sciences Alternative Funding LLC. According to Imprimis, the funding will go towards expansion and growth of the company's opthallogy and urology business. The company said the loan has an interest rate of 12.5 percent per year and monthly, interest-only payments for the first three years. Imprimis is led by Mark L. Baum.